Exelixis submits U.S. supplemental new drug application for Cabometyx^®(Cabozantinib) for the treatment of previously untreated advanced kidney cancer

This article or press release has no online content. Please download the associated documents for more information.

Understanding the true impact of living with FOP

Ipsen Announces Decision to Permanently Discontinue Distribution of NutropinAq® (somatropin) cartridges

Applications now open for the 2023 Golden Ticket Competition

Offering support to those impacted in Turkey & Syria

Choose your location: